Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.39 |
| ▸ | HRH2 | P25021 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21738354 | 0.94 | SPHK1 (0.41) | SPHK1MEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL22891062 | 0.87 | SPHK1 (0.40) | SPHK1MEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL20332790 | 0.83 | HRH3 (0.40) | MEN1ALDH1A1CYP2D6KMT2AHRH3 | |
| SCHEMBL26240693 | 0.82 | HRH2 (0.34) | HRH3HRH2HRH1GNAI3GNAO1 | |
| SCHEMBL22890988 | 0.81 | HRH3 (0.37) | ALDH1A1RAB9AHRH3HRH2HRH1 | |
| SCHEMBL22890929 | 0.80 | HRH3 (0.41) | SPHK1MEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL8501119 | 0.78 | HRH3 (0.43) | SPHK1MEN1ALDH1A1CYP2D6RAB9A | |
| SCHEMBL23183526 | 0.78 | HRH3 (0.39) | MEN1ALDH1A1KMT2AHRH3HRH1 | |
| SCHEMBL25870470 | 0.77 | LMNA (0.40) | MEN1CYP2D6KMT2ASLC6A4 | |
| SCHEMBL23183414 | 0.77 | ALDH1A1 (0.37) | ALDH1A1RAB9AHRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392405-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190048022-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048022-A1 | MACROCYCLIC IMMUNOMODULATORS | IL2, IL2RA, C3AR1 | SPHK1 571/4885MEN1 771/4885ALDH1A1 1925/4885 |
| US-10392405-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | SPHK1 571/4885MEN1 771/4885ALDH1A1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.